The committee will meet in open session to discuss Pfizer Inc.’s request to amend its Emergency Use Authorization (EUA) to allow for the use of the Pfizer-BioNTech COVID-19 vaccine in children 5 through 11 years of age.
Back to All Events
Earlier Event: October 14
Vaccines and Related Biological Products Advisory Committee
Later Event: October 28
Allergenic Products Advisory Committee